Close Menu

RNAi

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

Title: Construction of Protein-responsive shRNA/RNAi Control System Using RNP Motif
Patent Number: 8,871,437

NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a num

This story has been updated to include comments on the validity of the published research.

NEW YORK (GenomeWeb) — Two independent research teams this month published data revealing new roles for two key components of the canonical RNAi pathway — Argonaute-1 and Dicer — in the control of constitutive and alternate splicing, and in transcription termination and the maintenance of genomic

NEW YORK (GenomeWeb) — Alnylam Pharmaceuticals this week announced that it has launched a program called Alnylam Assist to provide free screening to patients with certain genetic diseases, namely the ones for which the company is developing treatments.

NEW YORK (GenomeWeb) — Tekmira Pharmaceuticals this week announced that it has started limited manufacturing of a new version of its siRNA Ebola treatment TKM-Ebola to specifically target the Guinea variant of the disease that is responsible for the current outbreak in Africa.

Title: Methods and Compositions for Increasing RNA Interference
Patent Number: 8,865,668
Filed: Feb. 20, 2009

NEW YORK (GenomeWeb) — Rosetta Genomics said today that it is collaborating with the Institute of Molecular Translational Medicine (IMTM) at Palacky University in the Czech Republic to validate and develop a new thyroid cancer diagnostic tool.

NEW YORK (GenomeWeb) — Biocept and Rosetta Genomics said this week that they will pair Biocept's circulating tumor cell isolation technology with Rosetta's microRNA analysis platforms to investigate the possibility of developing blood-based cancer diagnostics and therapeutic response assays.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.